12


/ Press Releases
2018.04
TWi is marketing Cephelexin Oral Suspension in partnership with a leading Taiwanese manufacturer
2017.12
Court Dismisses Patent Challenge to TWi’s Paragraph IV ANDA Filing for a Generic Equivalent to Axiron®
2017.11
TWi’s ANDA of Bupropion HCI ER Tablet has been approved by US FDA
2017.08
TWi Pharmaceuticals, Inc. Comments on Oxtellar XR® Ruling
2017.08
TWi successfully launches generic Guanfacine Hydrochloride ER Tablet in TWi label